Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for... Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen.
- Mechanism
- Curator reviewed
Lumiliximab is a chimeric macaque-human monoclonal antibody to CD23, a protein expressed on virtually all chronic lymphocytic leukemia (CLL) cells. CD23, also known as Fc epsilon RII, or FcεRII, is the "low affinity" receptor for IgE, an antibody isotype involved in allergy and resistance to parasites and is important in regulation of IgE levels. Unlike many of the antibody receptors, CD23 is a C-type lectin. It is found on mature B cells, activated macrophages, eosinophils, follicular dendritic cells and platelets.
- Primary indication
- Investigated for use/treatment in asthma and leukemia (lymphoid).Curator reviewed
- Formula / weight
- C2115H3252N556O673S16 · 47750.0 Da
- Also known as
- Gomiliximab · IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER · IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER · PRIMATIZED ANTI-CD23
- Code names
- IDEC-152 · ST-152
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Lumiliximab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account